Angiogenesis and the skin: A primer

Journal of the American Academy of Dermatology

Volumn 34, Issue 3, 1996, Pages 486-497

  Arbiser, Jack L ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ACIDIC FIBROBLAST GROWTH FACTOR; ALPHA2 INTERFERON; ANGIOGENIN; BASIC FIBROBLAST GROWTH FACTOR; CORTICOSTEROID; FIBRONECTIN; FUMAGILLIN; GLUCOCORTICOID; GROWTH FACTOR; HEPARIN; HEPARIN LYASE; INTEGRIN; INTERLEUKIN 12; INTERLEUKIN 8; ONCOSTATIN M; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; RECOMBINANT EPIDERMAL GROWTH FACTOR; SYNDECAN; THALIDOMIDE; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; BASAL CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; ENDOTHELIUM CELL; HEMANGIOMA; HUMAN; HUMAN CELL; INTRALESIONAL DRUG ADMINISTRATION; KAPOSI SARCOMA; LEG ULCER; LEPROSY; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; RAT; REVIEW; SKIN CANCER; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TOPICAL DRUG ADMINISTRATION;

EID: 0029863937     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(96)90444-2     Document Type: Review

References (116)

1. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267:10931-4.
2. Vlodavsky I, Korner G, Ishai-Michaeli R, et al. Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 1990;9:203-6.
3. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:442-7.
4. Klagsbrun M, Baird A. A dual receptor system is required for basic fibroblast growth factor activity. Cell 1991;67: 229-31.
5. Bernfield M, Kokenyesi R, Kato M, et al. Biology of the syndecans. Arm Rev Cell Biol 1992;8:365-93.
6. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Ann Rev Physiol 1991;53:217-39.
7. Ingber DE. Fibronectin controls capillary endothelial cell growth by modulating cell shape. Proc Natl Acad Sci U S A 1990;87:3579-83.
8. Pardanaud L, Altmann C, Kitos P, et al. Relationship between vasculogenesis, angiogenesis, and haemopoiesis during avian ontogeny. Development 1989;105:473-85.
9. Flamme I, Risau W. Induction of vasculogenesis and hematopoiesis in vitro. Development 1992;116:435-9.
10. Voyta JC, Via DP, Butterfield CE, et al. Identification and isolation of endothelial cells based upon their increased uptake of acetylated low-density lipoprotein. J Cell Biol 1984;99:2034-40.
11. Saigo PE, Rosen PP. The application of immunohistochemical stains to identify endothelial-lined channels in mammary carcinoma. Cancer 1987;59:51-4.
12. Little D, Said JW, Siegel RJ, et al. Endothelial cell markers in vascular neoplasms: an immunohistochemical study comparing factor VIII-related antigen, blood group specific antigens, 6-keto-PGF alpha, and Ulex europaeus 1 lectin. J Pathol 1986;149:89-95.
13. Folkman J, Haudenschild C, Zetter BR. Long-term culture of capillary endothelial cells. Proc Natl Acad Sci U S A 1979;76:5217-21.
14. Davison PM, Bensch K, Karasek MA. Isolation and growth of endothelial cells from the microvessels of the newborn human foreskin in cell culture. J Invest Dermatol 1980;75:316-21.
15. Kraling BM, Jimenez SA, Sorger T, et al. Isolation and characterization of microvascularization from the adult human dermis and from skin biopsies of patients with systemic sclerosis. Lab Invest 1994;71:745-54.
16. Gospodarowicz D. Fibroblast growth factor: chemical structure and biologic function. Clin Orthop 1990;257: 231-48.
17. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992;59:115-65.
18. Tekotte H, Engel M, Margolis RU, et al. Disaccharide composition of heparan sulfates: brain, nervous tissue storage organelles, kidney, and lung. J Neurochem 1994; 62:1126-30.
19. Elenius K, Maatta A, Salmivirta M, et al. Growth factors induce 3T3 cells to express bFGF-binding syndecan. J Biol Chem 1992;267:6435-41.
20. Elenius K, Vainio S, Laato M, et al. Induced expression of syndecan in healing wounds. J Cell Biol 1991;114:585-95.
21. O'Keefe EJ, Chin ML, Payne RE Jr. Stimulation of growth of keratinocytes by basic fibroblast growth factor. J Invest Dermatol 1988;90:767-9.
22. Ingber DE. Fibronectin controls capillary endothelial cell growth by modulating cell shape. Proc Natl Acad Sci U S A 1990;87:3579-83.
23. D'Amore PA. Modes of FGF release in vivo and in vitro. Cancer Metastasis Rev 1990;9:227-38.
24. Halaban R, Kwon BS, Ghosh S, et al. bFGF as an autocrine growth factor for human melanomas. Oncogene Res 1988;3:177-86.
25. Kandel J, Bossy-Wetzel E, Radvanyi F, et al. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991; 66:1095-104.
26. Bossy-Wetzel E, Bravo R, Hanahan D. Transcription factors junB and c-jun are selectively up-regulated and functionally implicated in fibrosarcoma development [Abstract]. Genes Dev 1992;12:2340-51.
27. Rogelj S, Weinberg RA, Fanning P, et al. Basic fibroblast growth factor fused to a signal peptide transforms cells. Nature 1988;331:173-5.
28. Becker D, Meier CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J 1989;8:3685-91.
29. Nguyen M, Watanabe H, Budson AE, et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994;86:356-61.
30. Nakajima M, Irimura T, Nicolson GL. Heparanases and tumor metastasis. J Cell Biochem 1988;36:157-67.
31. Fallon JF, Lopez A, Ros MA, et al. FGF-2: apical ectodermal ridge growth signal for chick limb development. Science 1994;264:104-7.
32. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-5.
33. Li L, Zhou J, James G, et al. FGF inactivates myogenic helix-loop-helix proteins through phosphorylation of a conserved protein kinase c site in their DNA-binding domains. Cell 1992;71:1181-94.
34. Hebda PA, Klingbeil CK, Abraham JA, et al. Basic fibroblast growth factor stimulation of epidermal wound healing in pigs. J Invest Dermatol 1990;95:626-31.
35. Greenhalgh DG, Sprugel KH, Murray MJ, et al. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol 1990;136:1235-46.
36. Johnson DE, Lee PL, Lu J, et al. Diverse forms of a receptor for acidic and basic fibroblast growth factors. Mol Cell Biol 1990;10:4728-36.
37. Wang JK, Gao G, Goldfarb M. Fibroblast growth factor receptors have different signaling and mitogenic potentials. Mol Cell Biol 1994;14:181-8.
38. Vainikka S, Partanen J, Bellosta P, et al. Fibroblast growth factor receptor 4 shows novel features in genomic structure, ligand binding, and signal transduction. EMBO J 1992;11:4273-80.
39. Orr-Urtreger A, Givol D, Yayon A, et al. Developmental expression of two murine fibroblast growth factor receptors, flg and bek. Development 1991;113:1419-34.
40. Yamaguchi TP, Harpal K, Henkemeyer M, et al. FGFR-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation. Genes Dev 1994;8: 3032-44.
41. Deng CX, Wynshaw-Boris A, Shen MM, et al. Murine FGFR-1 is required for early postimplantation growth and axial organization. Genes Dev 1994;8:3045-57.
42. Shiang R, Thompson LM, Zhu YZ, et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 1994;78:335-42.
43. Rousseau F, Bonaventure J, Legeai-Mallet L, et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 1994;371:252-4.
44. Shipley GD, Keeble WW, Hendrickson JE, et al. Growth of normal human keratinocytes and fibroblasts in serum-free medium is stimulated by acidic and basic fibroblast growth factor. J Cell Physiol 1989;138:511-8.
45. Mellin TN, Mennie RJ, Cashen DE, et al. Acidic fibroblast growth factor accelerates dermal wound healing. Growth Factors 1992;7:1-14.
46. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-12.
47. Yeo KT, Wang HH, Nagy JA, et al. Vascular permeability factor in guinea pig and human tumor and inflammatory effusions. Cancer Res 1993;53:2912-8.
48. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
49. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
50. Ballaun C, Weninger W, Uthman A, et al. Human keratinocytes express the three major splice forms of vascular endothelial growth factor. J Invest Dermatol 1995;104:7-10.
51. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
52. Plate KH, Breier G, Welch HA, et al. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-8.
53. Takeshita S, Pu LQ, Stein LA, et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1994; 90:228-34.
54. Jakeman LB, Winer J, Bennett GL, et al. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 1992;89:244-53.
55. Millauer B, Wizigman-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72:835-46.
56. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and flt-1, two receptors for VEGF. J Biol Chem 1994;269:26988-95.
57. Ishikawa F, Miyazono K, Hellman U, et al. Identification of an angiogenic activity and the cloning and expression of platelet derived endothelial cell growth factor. Nature 1989;338:557-62.
58. Palmer KA, Scheraga HA, Riordan JF, et al. A preliminary three-dimensional structure of angiogenin. Proc Natl Acad Sci U S A 1986;83:1965-9.
59. Vallee BL, Riordan JF. Chemical and biochemical properties of human angiogenin. Adv Exp Med Biol 1988; 234:41-53.
60. Zarling JM, Shoyab M, Marquardt K, et al. Oncostatin M: a growth factor regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci U S A 1986;83:9739-43.
61. Miles SA, Martinez-Maza O, Rezai A, et al. Oncostatin M as a potent mitogen for AIDS-Kaposi sarcoma derived cells. Science 1992;255:1432-4.
62. Gearing DP, Comeau MR, Friend DJ, et al. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 1992; 255:1434-7.
63. Cai J, Gill PS, Masood R, et al. Oncostatin M is an autocrine growth factor in Kaposi's sarcoma. Am J Pathol 1994;145:74-9.
64. Higashima S, Abraham JA, Miller J, et al. A heparin binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991;251:936-9.
65. Marikovsky M, Breuning K, Liu PY, et al. Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc Natl Acad Sci U S A 1993; 90:3889-93.
66. Katz MH, Alvarez AF, Kirsner RS, et al. Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growth. J AM ACAD DERMATOL 1991; 25:1054-8.
67. Naglich JG, Metherall JE, Russell DW, et al. Expression cloning of a diphtheria toxin receptor: identity with a heparin binding EGF-like growth factor precursor. Cell 1992;69:1051-61.
68. Falanga V, Eaglstein WH, Bucalo B, et al. Topical use of human recombinant epidermal growth factor in venous ulcers. J Dermatol Surg Oncol 1992;18:604-6.
69. Brown GL, Nanney LB, Griffen J, et al. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 1989;321:76-9.
70. Falanga V, Eaglstein WH. The "trap" hypothesis of venous ulceration. Lancet 1993;341:1006-8.
71. Phillips TJ, Dover JS. Leg ulcers. J AM ACAD DERMATOL 1991;25:965-87.
72. Tolsma SS, Volpert OV, Good DJ, et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993;122:497-511.
73. Tuszynski GP, Rothman VL, Deutsch AH, et al. Biological activities of peptides and peptide analogues derived from common sequences present in thrombospondin, properdin, and malarial proteins. J Cell Biol 1992;116:209-17.
74. Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989;56:345-55.
75. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 1990;87:6624-8.
76. Robson KJH, Hall JRS, Jennings MW, et al. A highly conserved amino-acid sequence in thrombospondin, properdin, and in proteins from sporozoites and blood stages of a human malaria parasite. Nature 1988;335:79-82.
77. Barnhill RL, McDougall AC. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J AM ACAD DERMATOL 1982; 7:317-23.
78. Enjolras O, Mulliken JB. The current management of vascular birthmarks. Pediatr Dermatol 1993;10:311-33.
79. D'Amato RJ, Lin CM, Flynn E, et al. 2-methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci U S A 1994;91:3964-8.
80. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990;348:555-7.
81. Kusaka M, Sudo K, Fujita T, et al. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 1991;174: 1070-6.
82. Antoine N, Greimers R, De Roanne C, et al. AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res 1994;54:2073-6.
83. Maione TE, Sharpe RJ. Development of angiogenesis inhibitors for clinical applications. Trends Pharmacol Sci 1990;11:457-61.
84. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor 4 and related peptides. Science 1990;247:77-9.
85. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315-28.
86. Voest EE, Kenyon BM, O'Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581-6.
87. Bernfield M, Hinkes MT, Gallo RL. Developmental regulation of the syndecans: possible function and regulation. Development 1993;(suppl)205-12.
88. Gallo RL, Ono M, Povsic T, et al. Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc Natl Acad Sci U S A 1994;91:11035-9.
89. Brooks PC, Montgomery A, Rosenfeld M, et al. Integrin aVb3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
90. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integral aVb3 for angiogenesis. Science 1994; 264:569-71.
91. Takahashi K, Mulliken JB, Kozakewich HPW, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994;93:2357-64.
92. Shorr N, Seiff SR. Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surg 1986;17:229-31.
93. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life threatening hemangiomas of infancy. N Engl J Med 1992;326:1456-63.
94. White CW, Sondheimer HM, Crouch EC, et al. Treatment of pulmonary hemangiomatosis with recombinant interferon alpha-2a. N Engl J Med 1989;320:1197-200.
95. Barnhill RL, Fandrey K, Levy MA, et al. Angiogenesis and tumor progression of melanoma: quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest 1992;67:331-7.
96. Schultz-Hector S, Haghayegh S. Beta-fibroblast growth factor expression in human and murine squamous cell carcinomas and its relationship to regional endothelial cell proliferation. Cancer Res 1993;53:1444-9.
97. Schadendorf D, Moller A, Algermissen B, et al. Interleukin-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993;151:2667-75.
98. Singh RK, Gutman M, Radinsky R, et al. Expression of interleukin-8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994; 54:3242-7.
99. Graves DT, Barnhill R, Galanopoulos T, et al. Expression of monocyte chemotactic protein-1 in human melanoma in vivo. Am J Pathol 1992;140:9-14.
100. Zachariae CO, Thestrup-Pedersen K, Matsushima K. Expression and secretion of leukocyte chemotactic cytokines by normal human melanocytes and melanoma cells. J Invest Dermatol 1991;98:593-9.
101. Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis, and cancer therapy. Anticancer Drugs 1995;6:3-18.
102. Grob JJ, Collet AM, Munoz MH, et al. Treatment of large basal cell carcinomas with intralesional interferon alfa-2a. Lancet 1988;1:878-9.
103. Greenway HT Jr, Cornell RC. Interferon: coming of age. Arch Dermatol 1990;126:1080-2.
104. Edwards L, Tucker SB, Parednia D, et al. The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinoma. Arch Dermatol 1990; 126:1029-32.
105. Wickramasinghe L, Hindson TC, Wacks H. Treatment of neoplastic skin lesions with intralesional interferon. J AM ACAD DERMATOL 1989;20:71-4.
106. Stenquist B, Wennberg A-M, Gisslén H, et al. Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery. J AM ACAD DERMATOL 1992;27:65-9.
107. Lippman SM, Shimm DS, Meyskins FL Jr. Nonsurgical treatment for skin cancer: retinoids and alpha interferon. J Dermatol Surg Oncol 1988;14:862-9.
108. Beuchner SA. Intralesional interferon alpha 2b in the treatment of basal cell carcinoma. J AM ACAD DERMATOL 1991;24:731-4.
109. Lippman SM, Parkinson DR, Itri LM, et al. 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992;84:235-41.
110. Kruit WH, Goey SH, Monson JR, et al. Clinical experience with the combined use of recombinant interleukin 2 and interferon alfa 2a in metastatic melanoma. Br J Hematol 1991;79:84-6.
111. Singh RK, Gutman M, Bucana CD, et al. Interferons a and b down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A 1995;92:4562-6.
112. Malhotra R, Stenn KS, Fernandez LA, et al. Angiogenic properties of normal and psoriatic skin associated with epidermis, not dermis. Lab Invest 1989;61:162-5.
113. Braverman IM, Sibley J. Role of the microcirculation in the treatment and pathogenesis of psoriasis. J Invest Dermatol 1982;78:12-7.
114. Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180:1141-6.
115. Nickoloff BJ, Mitra RS, Varani J, et al. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994; 144:820-8.
116. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995; 1:149-55.